National and Kapodistrian University of Athens
Η επίδραση της συλλοίμωξης από ηπατοτρόπους και ηπατιτιδομιμητικούς ιούς στη φυσική εξέλιξη της χρόνια HBV και HCV ηπατοπάθειας
Abstract
dc:descriptionOccult HBV infection (HBV) in patients with chronic hepatitis C (HCV) has been reported to be clinically significant and contribute to chronic liver damage, including cirrhosis and hepatocellular carcinoma (HCC) and may be associated with worse response tο antiviral treatment. Hepatomimetic viruses, such as CMV and EBV may influence the severity of liver disease and treatment response in HCV and HBV-infected patients. The aim of this study was to evaluate the possible impact of occult HBV infection on clinical outcome of liver disease and the response to combination treatment in chronic HCV patients as well as to reveal the clinical significance of latent CMV and /or EBV infection in the progression of liver disease and the response to treatment in HCV and HBV patients. Seventy-five HBsAg negative patients with HCV infection confirmed by RT-PCR RNA and liver biopsy were evaluated. Serological assays of antiHBc and antiHBs were performed. Serum HBV DNA was evaluated using COBAS AMPLICOR HBV Monitor assay (cut off: 200 copies /ml). The values of AST, ALT, γGT, albumin, PLTs were determined. HCV genotypes were identified according to the Simmods et al. criteria. Titers of anti-CMV IgG and anti-VCA IgG were eveluated to assess “silent” infection of CMV and EBV by ELFA and ELISA, respectively. All of them had received combination therapy with peg-interferon-a plus ribavirin. The presence of HBV-DNA was correlated with epidemiological, clinical, laboratory data, HCV genotype, serological markers of HBV infection and response to the above mentioned combination therapy for HCV patients. Serum HBV DNA was detected in 33 (44.00%) HCV patients with mean:3152 IU/ml and range:260-8970 IU/ml. The prevalence of occult HBV infection was particularly high among anti-HBc (64.51%) or antiHBc plus anti-HBs positive (45.83%) patients. Occult HBV infection was also detected in 2 (10.00 %) patients negative for all HBV serum markers, although the HBV DNA titer was particularly low (<700 IU/ml). We observed that HCV patients with occult HBV infection had higher aminotransferases and γGT than patients without HBV DNA. The prevalence of occult HBV infection was in parallel with the severity of chronic liver disease. There was no significant difference in gender, age and genotype distribution in relation to the presence or absence of occult HBV infection and the response to treatment. In addition, the prevalence of latent CMV and EBV infection paralleled the severity of liver disease of HCV and HBV patients. It was higher among patients with cirrhosis and HCC, and lower among patients with normal aminotransferases. However, the difference was not statistically significant. Although the relation between genotype and treatment response is well-defined, our study revealed that other factors, such as latent HBV, CMV and/or EBV latent infection contribute to the treatment response of HCV patients. Moreover, we evaluated 30 HBV patients for occult infection with CMV and/or EBV in order to assess the possible role of occult infection. Νo statistically significant results were found concerning clinical stage and response to nucleos(t)ide analogues among HBV patients with or without occult CMV or EBV infection probably because of the small number of patients included. However, a trend towards worse clinical stage (cirrhosis or HCC) was found among HBv patients with occult CMV and/or EBV latent infection. In conclusion, occult HBV infection may influence the course of chronic HCV infection, although our results were not statistically significant. However, the virological response to combination treatment was associated with worse outcome in HCV patients with occult HBV infection. This probably means that low level HBV does interfere with the response to combination therapy against HCV, as the difference was statistically significant. In addition, latent infections by hepatomimetic viruses may play a crucial role in the progression of liver disease in HCV and HBV-infected patients and may deteriorate the prognosis of those patients in relation with the response to treatment. However, further studies with longer follow-up are necessary in order to provide more information about the impact of occult infections by hepatotropic and/or hepatomimetic viruses in the progression and treatment response for both chronic HBV and HCV infection.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gerakari, Styliani
- Γερακάρη, Στυλιανή
Subjects
dc:subject × 16- Συλλοιμώξεις ιών
- Λανθάνουσα HBV λοίμωξη
- Λανθάνουσα CMV λοίμωξη
- Λανθάνουσα EBV λοίμωξη
- Επιπολασμός συλλοιμώξεων
- Επίδραση συλλοιμώξεων στην ανταπόκριση στην HCV / HBV αντιική αγωγή
- Viral coinfections
- Occult HBV infection
- Latent CMV infection
- Latent EBV infection
- Epidemiology of coinfections
- The effect of coinfections in treatment response of HCV / HBV patients
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29986